Research Article

Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer's Gold Data

Volume: 21 Number: 4 December 29, 2025
EN

Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer's Gold Data

Abstract

This study aimed to experimentally compare dosimetric measurement data obtained after linac replacement in a Tomotherapy HiArt system with the "gold data" provided by the manufacturer, according to the acceptance criteria recommended by AAPM TG-148. Energy quality (TPR1.5/10), percentage depth dose (PDD), transverse and longitudinal beam profiles, and patient treatment plan quality assurance (QA) measurements were performed and compared with gold data. The difference between the gold and measured data in the energy quality measurement was 0.5%. In the PDD measurements, the difference in dmax values remained at a maximum of 0.9 mm, and the PDD20/10 ratio remained below 1%. Agreement within the 1% tolerance limits was also observed in the transverse and longitudinal profiles. Furthermore, the patient QA measurements were in agreement with the results obtained using the previous linac. The findings demonstrated that all measurements remained within the TG-148 criteria, indicating that linac replacement did not significantly affect system performance. These results confirmed that the TomoTherapy HiArt system provides reliable and accurate dosimetric measurements following linac replacement, ensuring consistent and high-quality patient treatment delivery.

Keywords

References

  1. [1]. Balog J, Olivera G, Kapatoes J. 2003. Clinical helical tomotherapy commissioning dosimetry. Med Phys;30(12):3097–106.
  2. [2]. Jeraj R, Mackie TR, Balog J, John Balog, 2004. Gustavo Olivera, Dave Pearson, Jeff Kapatoes, Ken Ruchala, Paul Reckwerdt. Radiation characteristics of helical tomotherapy. Med Phys; 31(2):396–404.
  3. [3]. Langen KM, Papanikolaou N, Balog J, Crilly R, Followill D, Goddu SM, Grant W, Olivera G, Ramsey CR, Shi C. 2010. QA for helical tomotherapy: report of the AAPM Task Group 148. Med Phys. Sep;37(9):4817-53.
  4. [4]. Zhao YL, Mackenzie M, Kirkby C, Fallone BG. 2008. Monte Carlo calculation of helical tomotherapy dose delivery. Med Phys; 35(8):3491–500.
  5. [5]. Jean L. Peng,a Michael S. Ashenafi, Daniel G. McDonald, Kenneth N. Vanek. 2015. Assessment of a three-dimensional (3D) water scanning system for beam commissioning and measurements on a helical tomotherapy unit. Journal Of Applıed Clınıcal Medıcal Physıcs, Volume 16, Number 1.
  6. [6]. Göksel E, Barlaz Us S, Akdeniz Y, Bozca R, Elçim Y, Gani Z, Güray G, Dede Karakoç N, Nalbant N, Toksoy T, Yeşil A. 2024. Guide For Quality Control and Quality Assurance Tests in Tomotherapy/Radixact Systems. Turk J Oncol 2024;39(Supp 1):31–5.
  7. [7]. Günhan B. 2010. Helikal Tomoterapi’de Hasta Kalite Kontrolünde Dozimetrik Yöntemlerin Karşılaştırılması. İstanbul Ünversitesi Sağlık Bilimleri Enstitüsü Doktora Tezi İstanbul.
  8. [8]. Sharma SD. 2011. Unflattened photon beams from the standard flattening filter free accelerators for radiotherapy: Advantages, limitations and challenges Med Phys. 2011 Jul-Sep;36(3):123–125.

Details

Primary Language

English

Subjects

Biomedical Instrumentation

Journal Section

Research Article

Publication Date

December 29, 2025

Submission Date

February 4, 2025

Acceptance Date

May 29, 2025

Published in Issue

Year 2025 Volume: 21 Number: 4

APA
Kaya Pepele, E. (2025). Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science, 21(4), 70-78. https://doi.org/10.18466/cbayarfbe.1633397
AMA
1.Kaya Pepele E. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. CBUJOS. 2025;21(4):70-78. doi:10.18466/cbayarfbe.1633397
Chicago
Kaya Pepele, Eda. 2025. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison With Manufacturer’s Gold Data”. Celal Bayar University Journal of Science 21 (4): 70-78. https://doi.org/10.18466/cbayarfbe.1633397.
EndNote
Kaya Pepele E (December 1, 2025) Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science 21 4 70–78.
IEEE
[1]E. Kaya Pepele, “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data”, CBUJOS, vol. 21, no. 4, pp. 70–78, Dec. 2025, doi: 10.18466/cbayarfbe.1633397.
ISNAD
Kaya Pepele, Eda. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison With Manufacturer’s Gold Data”. Celal Bayar University Journal of Science 21/4 (December 1, 2025): 70-78. https://doi.org/10.18466/cbayarfbe.1633397.
JAMA
1.Kaya Pepele E. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. CBUJOS. 2025;21:70–78.
MLA
Kaya Pepele, Eda. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison With Manufacturer’s Gold Data”. Celal Bayar University Journal of Science, vol. 21, no. 4, Dec. 2025, pp. 70-78, doi:10.18466/cbayarfbe.1633397.
Vancouver
1.Eda Kaya Pepele. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. CBUJOS. 2025 Dec. 1;21(4):70-8. doi:10.18466/cbayarfbe.1633397